Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash from Investing Activities: 2012-2024

Historic Cash from Investing Activities for Akebia Therapeutics (AKBA) over the last 12 years, with Dec 2024 value amounting to -$33,000.

  • Akebia Therapeutics' Cash from Investing Activities fell 3750.00% to -$77,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$51,000, marking a year-over-year decrease of 100.26%. This contributed to the annual value of -$33,000 for FY2024, which is N/A change from last year.
  • Per Akebia Therapeutics' latest filing, its Cash from Investing Activities stood at -$33,000 for FY2024, which was up 71.05% from -$114,000 recorded in FY2022.
  • Akebia Therapeutics' 5-year Cash from Investing Activities high stood at $39.9 million for FY2021, and its period low was -$40.0 million during FY2020.
  • Moreover, its 2-year median value for Cash from Investing Activities was -$73,500 (2022), whereas its average is -$73,500.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 118.94% in 2020, then soared by 199.84% in 2021.
  • Yearly analysis of 4 years shows Akebia Therapeutics' Cash from Investing Activities stood at -$40.0 million in 2020, then soared by 199.84% to $39.9 million in 2021, then tumbled by 100.29% to -$114,000 in 2022, then reached -$33,000 in 2024.